Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15818431 | 0.79 | TSHR (0.51) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL17212822 | 0.79 | TSHR (0.49) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL6449584 | 0.78 | TSHR (0.49) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL6446161 | 0.77 | TSHR (0.47) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL4044979 | 0.77 | TSHR (0.47) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL8350092 | 0.77 | TSHR (0.47) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL10624505 | 0.77 | TSHR (0.51) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL7279994 | 0.75 | TSHR (0.49) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL12206737 | 0.75 | TSHR (0.55) | TSHRRECQLSMN1; SMN2USP2CYP2C19 | |
| SCHEMBL296555 | 0.73 | TSHR (0.53) | TSHRRECQLSMN1; SMN2USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | TSHR 2585/4885RECQL 774/4885SMN1; SMN2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.